• E-mail
• Print
• RSS

Kidney cancer treatment shows promise for lung cancer

Respiratory Care Weekly, June 7, 2006

More than a third of the 63 treatment-resistant, recurrent, and advanced lung-cancer patients who enrolled in a therapy trial with kidney cancer drug sunitinib showed partial responses or disease stabilization, according to research. The drug blocks a tumor's ability to develop new blood vessels, said researchers at the American Society of clinical Oncologists annual meeting this week. About 100 patients have been treated so far.

"As a single agent, this drug worked in a difficult group of patients whose advanced disease had been previously treated with other chemotherapies and whose options were limited," said Mark A. Socinski, lead researcher and associate professor of medicine at the University of North Carolina at Chapel Hill. Research remains in the early stages for determining safe dosages, researchers said. Length-of-survival data in this study is also still pending.

• E-mail to a Colleague
• Print
• RSS
• Archive